stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) EPS (diluted)
ICON PLC's EPS (diluted) for fiscal 2025 was $2.90, down 67.4% from $8.90 in fiscal 2024. Over the twelve months to 30 September 2026 it was $5.81. Over the past ten years it has ranged from $2.25 (fiscal 2021) to $8.90 (fiscal 2024); the current reading is higher than 18% of that period. ICON PLC ranks 11th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.90 | (67.42%) |
| FY2024 | $8.90 | 32.84% |
| FY2023 | $6.70 | 9.30% |
| FY2022 | $6.13 | 172.44% |
| FY2021 | $2.25 | (63.41%) |
| FY2020 | $6.15 | (9.43%) |
| FY2019 | $6.79 | 11.49% |
| FY2018 | $6.09 | 18.71% |
| FY2017 | $5.13 | 7.55% |
| FY2016 | $4.77 | 19.85% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.58 | 67.85% |
| Jun 2026 | $0.94 | (30.88%) |
| Mar 2026 | $1.36 | (29.53%) |
| Dec 2025 | $1.93 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MEDP Medpace Holdings, Inc. compare | $18.04 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| ILMN Illumina, Inc. compare | $5.81 |
| ICLR ICON PLC | $5.81 |
| RVTY Revvity Inc. compare | $2.26 |
| QGEN QIAGEN N.V. compare | $1.95 |
| CRL Charles River Laboratories International, Inc. compare | $0.93 |
| GH Guardant Health, Inc. compare | −$3.68 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ICLR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement